Sasanlimab Prolongs EFS When Combined with BCG Induction and Maintenance in Patients with BCG-naive High-Risk NMIBC By Ogkologos - July 22, 2025 520 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CREST study Source RELATED ARTICLESMORE FROM AUTHOR European Parliament Adopts Its Position on the Critical Medicines Act, Strengthening Security of Cancer Care in Europe ESMO Raises Key Issues on Cancer Prevention and Care at the WHO Executive Board Meeting Noninferiority of OS with 3 Months Compared to 6 Months of Adjuvant Chemotherapy for Patients with High-Risk Stage III Colorectal Cancer MOST POPULAR Efficacy of ICI Combined with Chemotherapy in Patients with Advanced Penile... October 1, 2025 The Late Alex Trebek’s Wardrobe Is Being Given to Homeless Men... February 25, 2021 Steps towards a smokefree society August 31, 2022 Terminally Ill ‘Flamingo Lady’ Gets Emotional After Dying Wish Comes True September 27, 2021 Load more HOT NEWS ASCO Annual Meeting 2023: Trastuzumab Deruxtecan Effectively Treats HER2-Expressing Tumors and... Our nurses answer your frequently asked questions about cancer New on NCI’s Websites for July 2021 ΚΑΡΚΙΝΟΣ ΤΟΥ ΝΕΦΡΟΥ
